FDA Review Of Fertility Drug Use For Safety Signals To Use IMS Data
Executive Summary
FDA's Office of Drug Safety is conducting a nationwide analysis of the use of fertility drugs as a basis for an evaluation of post-marketing safety issues with fertility treatments
You may also be interested in...
FDA Expects To Act On New Drug Safety Cooperative Agreements By Sept. 30
FDA intends to sign new contracts that will provide the agency access to population-based data resources through its cooperative agreement program by Sept. 30
FDA Expects To Act On New Drug Safety Cooperative Agreements By Sept. 30
FDA intends to sign new contracts that will provide the agency access to population-based data resources through its cooperative agreement program by Sept. 30
Bextra Withdrawn At FDA’s Request; Pfizer Holds Out Hope For Return
Pfizer will have to show a "unique" benefit associated with Bextra in order to justify a return to the U.S. market, FDA Office of New Drugs Director John Jenkins said during an April 7 media conference call announcing the withdrawal of the COX-2 inhibitor